Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers.
Recommendations for the management of cutaneous adverse effects of inhibitors of the epidermal growth factor receptor (EGFR) are urgently needed. In this context an expert panel of German dermatologists recently proposed a 3-step management concept based on personal experience and a current literature consensus. While steps 1 and 2 addressed general and preventive measures, as well as the therapy that can be performed by the primary treating physician, here we address the management of challenging cases (step 3) that do not respond well to basic measures and should be referred to an experienced dermatologist.
Hautklinik, Universitätsklinikum Düsseldorf, Germany. bernhard.homey@uni-duesseldorf.de
Bernhard
B
Homey
Peter Arne
PA
Gerber
Andreas
A
Wollenberg
Thomas
T
Dirschka
Jessica C
JC
Hassel
Edwin
E
Bölke
Axel
A
Hauschild
Ralf
R
Gutzmer
D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D003880:Dermatology / Q000592:standards*; D003875:Drug Eruptions / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D024841:Fluoroquinolones / Q000627:therapeutic use; D005858:Germany; D006801:Humans; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D012176:Retinoids / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000891:Anti-Infective Agents, Local; D002511:Cephalosporins; D024841:Fluoroquinolones; D047428:Protein Kinase Inhibitors; D012176:Retinoids; D066246:ErbB Receptors